US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by aTyr Pharma, Inc.

News headline image
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma to Participate in September Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Research Study with Stanford Medicine
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers ATYR
News headline image
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma to Participate in April Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE
News headline image
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
From aTyr Pharma, Inc.
Via GlobeNewswire
Tickers LIFE